Immunotherapy and chemo for colorectal cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), growth factors, and chemotherapy (CapeOX) for people whose colorectal cancer has spread only to the liver. The goal is to see if this combination shrinks the tumors enough to allow surgery to remove them completely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colon or rectal cancer that has spread to the liver (and nowhere else at the time of starting treatment).
- Your tumor is a type called 'pMMR' or 'MSS' or 'MSI-L' (your doctor will know this).
- You have not had any chemotherapy or immunotherapy for this cancer before.
- You do not have a serious autoimmune disease or a lung condition that needs steroid treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a combination of three chemotherapy drugs (liposomal irinotecan, oxaliplatin, and capecitabine) given directly into the liver blood vessel after surgery to remove colorectal cancer that has spread to the liver. The goal is to reduce the chance of cancer coming back.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.